Clinical trial · Observational
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
Endometrial cancer (EC) is the most common gynecological malignancy in high-income countries. Prognosis and treatment are dictated by cancer histological subtype and grade coupled with surgical staging as described by Surgical International Federation of Gynecology and Obstetrics (FIGO) staging system. Surgery is the elective standard treatment and used for staging of EC. The purpose of this study is to collect images from a simultaneous PET/MRI study from which to extrapolate a preoperative, non-invasive, prognostic model.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrium Cancer | Endometrial Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- MRI evaluation
- timeFrame
- 0-2 years
- description
- Measure tumor volume and correlate to surgical specimen
- measure
- MRI imaging
- timeFrame
- 0-2 years
- description
- Changes in ADC normale versus tumor myometrium
- measure
- MRI imaging evaluation
- timeFrame
- 0-2 years
- description
- Depth of myometrial invasion
- measure
- DCE-MRI perfusion parameters
- timeFrame
- 0-2 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histopathological confirmation of a primary endometrial cancer * age \> 18 years * no contraindication to surgery (comorbidity, contraindication or lack of consent) * no contraindication to preoperative imaging * visible tumor at imaging * signed inform consent. Exclusion Criteria: * patients unsuitable for surgical intervention (comorbidity, contraindication or lack of consent, poor performance status) * age \< 18 years, c) inability to complete the needed imaging examination (ie, severe claustrophobia) * any additional medical condition that may significantly interfere with study compliance * all the contraindication for MRI (ie, pacemaker).
References
Publications (3)
- BACKGROUNDKitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [(1)(8)F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012 May;39(5):840-5. doi: 10.1007/s00259-011-2057-9. Epub 2012 Feb 17. PMID 22349717
- BACKGROUNDNakamura K, Kodama J, Okumura Y, Hongo A, Kanazawa S, Hiramatsu Y. The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer. Int J Gynecol Cancer. 2010 Jan;20(1):110-5. doi: 10.1111/IGC.0b013e3181c3a288. PMID 20130510
- DERIVEDBezzi C, Ironi G, Russo T, Candotti G, Fallanca F, Sabini C, Samanes Gajate AM, Ghezzo S, Bergamini A, Sant'Angelo M, Bocciolone L, Brembilla G, Scifo P, Taccagni G, Catalano OA, Mangili G, Candiani M, De Cobelli F, Chiti A, Mapelli P, Picchio M. [18F]FDG PET/MRI in Endometrial Cancer: Prospective Evaluation of Preoperative Staging, Molecular Characterization and Prognostic Assessment. Cancers (Basel). 2026 Jan 16;18(2):280. doi: 10.3390/cancers18020280. PMID 41595203